CytoSorbents flags new CytoSorb clinical data presentations at EACTS, ESICM conferences

• CytoSorbents flagged new clinical data on its CytoSorb blood purification device for presentation at EACTS and ESICM in October 2026.
• Results have not yet been presented; the company outlined scheduled talks spanning cardiac surgery bleeding risk, post-surgery shock, ECMO-related inflammation, sepsis, ARDS.
• Presentations are set to highlight real-world registry experience, with outcomes framed around improved management of hyperinflammation and organ dysfunction in critical illness.
• The updates center on the COSMOS Registry, a key evidence-building program that could support broader clinical adoption across cardiac surgery and ICU use-cases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609300700PR_NEWS_USPR_____NY60273) on September 30, 2026, and is solely responsible for the information contained therein.